CryoPort (NASDAQ:CYRX) Stock Crosses Above Two Hundred Day Moving Average - Here's What Happened
CryoPort (NASDAQ:CYRX) stock recently crossed above its 200-day moving average, trading as high as $15.33 before closing at $15.09. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $18.00, despite the company slightly missing quarterly EPS estimates but exceeding revenue expectations. Insider selling by a director and the CFO has been noted, while institutional investors have increased their holdings.
Form 8K Cryoport Inc For: 6 August By Investing.com
This article reports on the filing of a Form 8K by Cryoport Inc. on August 6th. The brief piece includes the company's stock symbol, CYRX, and its current performance of +0.79%.
Cryoport (CYRX): Cadian Capital group reports 5.8% beneficial ownership stake
Cadian Capital Management, LP, Cadian Capital Management GP, LLC, and Eric Bannasch (collectively, the reporting persons) have disclosed a beneficial ownership stake of 5.8% in Cryoport, Inc. (CYRX). As of June 30, 2026, this group beneficially owned 2,920,681 shares of Cryoport common stock, out of 50,648,491 shares outstanding. The shares are directly held by Cadian Master Fund L.P. and Cadian Opportunities Master Fund LP, with Cadian Capital Management, LP exercising exclusive voting and investment power.
Cryoport (CYRX) Q2 2026 Earnings Call Transcript
Cryoport (CYRX) reported strong Q2 2026 earnings, with total revenue reaching $49 million, driven by a 15% year-over-year growth in its Life Science Services segment. The company achieved positive adjusted EBITDA of $400,000, marking a significant milestone in its pathway to profitability. Cryoport affirmed its full-year 2026 revenue guidance of $192 million to $196 million, citing continued strong demand and strategic initiatives including new facility launches and advanced product development.
Cryoport (Nasdaq:CYRX) - Stock Analysis
Cryoport (Nasdaq:CYRX) provides temperature-controlled supply chain solutions for biopharma, animal health, and reproductive medicine. The company has a market cap of US$766.3m, with analysts largely agreeing the stock price will rise by 26.8%, though it is currently unprofitable and facing significant insider selling. Recent updates include affirmed revenue guidance for 2026 and the selection of its IntegriCell cryopreservation services by Verismo Therapeutics.
Morgan Stanley (CYRX) updates Cryoport stake to about 4.5% in 13G/A filing
Morgan Stanley and its affiliate, Morgan Stanley Capital Services LLC, have reduced their stake in Cryoport, Inc. (CYRX) to below 5%, as detailed in a recent 13G/A SEC filing. Morgan Stanley now reports shared voting power over approximately 2.19 million shares and dispositive power over 2.24 million shares, representing 4.5% of the class. This filing indicates that both entities have ceased to be beneficial owners of more than five percent of Cryoport's common stock.
Cryoport president, CEO Shelton sells $429k in stock via 10b5-1 plan
Cryoport's President and CEO, Jerrell Shelton, sold 28,800 shares of company stock for approximately $429,384 on August 11, 2026, via a Rule 10b5-1 trading plan. This sale occurred after Cryoport shares surged significantly, trading near their 52-week high. The company recently reported strong Q2 earnings, with revenue aligning with expectations and positive adjusted EBITDA, indicating steady demand and progress.
CryoPort Inc (CYRX) President and CEO Jerrell Shelton Sells 28,800 Shares
CryoPort Inc's President and CEO, Jerrell Shelton, sold 28,800 shares of CYRX for approximately $429,408. This transaction is part of a larger trend of insider selling at the company, with no insider purchases in the last year, suggesting insiders might view the stock as overvalued. GuruFocus's valuation model indicates the stock is "Significantly Overvalued," trading at $14.91 compared to its GF Value of $11.03, despite three gurus recently adding to their positions.
Cryoport president, CEO Shelton sells $429k in stock via 10b5-1 plan
Cryoport's President and CEO, Jerrell Shelton, sold 28,800 shares of the company's common stock for approximately $429,384 on August 11, 2026, through a pre-arranged 10b5-1 trading plan. This sale occurred as Cryoport's shares have seen significant growth, up 76% over the past year. The company recently reported strong Q2 earnings, with revenue of $49 million and a positive adjusted EBITDA of $400,000, maintaining its full-year revenue guidance.
Jerrell Shelton Sells 28,800 Shares of CryoPort (NASDAQ:CYRX) Stock
CryoPort CEO Jerrell Shelton sold 28,800 shares of the company's stock for over $429,000, reducing his direct holdings by 2.34%. This transaction was conducted under a pre-arranged trading plan. Despite missing earnings estimates slightly, CryoPort's revenue exceeded expectations, and analysts maintain a "Moderate Buy" rating with an average price target of $18.00.
Cryoport (CYRX) CEO Jerrell Shelton sells 28,800 shares under 10b5-1 plan
Cryoport, Inc. CEO Jerrell Shelton sold 28,800 shares of common stock on August 11, 2026, at a weighted average price of $14.9092 per share. This sale was conducted automatically under a Rule 10b5-1 trading plan adopted on May 11, 2026, and terminated on the day of the sale. Following this transaction, Shelton directly owns 1,201,814 shares of Cryoport common stock.
Cryoport (NASDAQ: CYRX) plans sale of 28,800 common shares
Cryoport, Inc. has filed a Form 144 disclosing a planned sale of up to 28,800 common shares on NASDAQ, with an aggregate value of $426,816.00. The shares, originating from restricted stock units and previously exercised holdings acquired on February 29, 2012, are intended to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services. This filing indicates a neutral impact and sentiment according to Rhea-AI.
Assenagon Asset Management S.A. Has $18.09 Million Holdings in CryoPort, Inc. $CYRX
Assenagon Asset Management S.A. reduced its stake in CryoPort, Inc. (NASDAQ:CYRX) by 23% in the second quarter, now holding 1.15 million shares valued at $18.09 million. Despite this, institutional investors collectively own 92.9% of the company, and analysts maintain a "Moderate Buy" consensus with an average price target of $18.00. CryoPort reported second-quarter revenue of $49.0 million, slightly exceeding expectations, but missed EPS estimates with a $0.20 per share loss.
CryoPort, Inc. Stock 12‑Month Price Target Raised to $19.33, Implies 31% Upside
CryoPort, Inc.'s stock price target has been increased to $19.33 by analysts, up from $17.06, with a potential upside of 31% based on the recent closing price. The consensus rating from 9 analysts remains "Buy," with 8 recommending a Buy and 1 a Hold.
Cryoport, Inc. (CYRX) stock price, news, quote and history
This article provides comprehensive financial information for Cryoport, Inc. (CYRX), including its stock price, news, and historical data. It details the company's overview, its services in temperature-controlled supply chain solutions for the life sciences industry, and its recent performance metrics, analyst ratings, and financial highlights. The article also offers comparison tools with similar companies in the Integrated Freight & Logistics sector.
Cryoport Releases Q2 2026 Financial Results
Cryoport, Inc. announced its Q2 2026 financial results, reporting a loss per share of $0.20, matching analyst estimates, with a net loss of $8.3 million on revenues of $49.0 million. Revenue increased by 8.0% year-over-year, driven by its Life Sciences Services segment, which grew 15.0% and supported 779 CGT clinical trials. Despite the current loss, Wall Street analysts maintain a positive outlook on the stock, with 8 buy ratings.
Needham & Company LLC Issues Positive Forecast for CryoPort (NASDAQ:CYRX) Stock Price
Needham & Company LLC has raised its price target for CryoPort (NASDAQ:CYRX) from $15 to $19, maintaining a "buy" rating and indicating a potential upside of approximately 29%. This positive outlook aligns with other analysts, resulting in a consensus "Moderate Buy" rating and an average target price of $17. Despite exceeding revenue expectations with $48.97 million, the company reported a slightly higher loss per share than anticipated, while insider selling and significant institutional ownership were also noted.
Cryoport (NASDAQ:CYRX) Reports In-Line Q2 Results as Stock Edges Higher
Cryoport (NASDAQ:CYRX) reported Q2 2026 results that were largely in line with analyst expectations, with revenue of $48.97 million against a consensus of $49.17 million and non-GAAP EPS of -$0.20 versus an expected -$0.1977. The stock reacted positively, moving about 1.3% higher in after-hours trading, suggesting the market did not find significant negative surprises. Investors are now focused on the company's growth outlook and path to profitability, especially in the context of its negative EPS and continued demand for its temperature-controlled logistics services.
Cryoport, Inc. 1Q 2026: Revenue $48.97M, EPS ($0.2) — 10-Q Summary
Cryoport, Inc. reported its first-quarter 2026 results, showing a revenue increase to $48.97 million, but recorded a net loss and a diluted loss per share of ($0.2) compared to a profit in the prior year. Revenue growth was primarily driven by its Life Sciences Services segment, including BioLogistics and BioStorage/BioServices, and commercial cell and gene therapy revenue. The company also completed the divestiture of CRYOPDP and is investing in MVE freezers and digital/AI capabilities.
Cryoport Inc earnings missed by $0.01, revenue topped estimates
Cryoport Inc (NASDAQ: CYRX) reported Q2 EPS of $-0.20, missing analyst estimates by $0.01, but its revenue of $48.97 million topped the consensus estimate of $48.21 million. The company's stock price has shown strong performance, up 7.94% in the last 3 months and 79.02% in the last 12 months. InvestingPro assesses Cryoport Inc's financial health as "good performance."
Earnings Flash (CYRX) Cryoport, Inc. Reports Q2 Revenue $49.0M, vs. FactSet Est of $48.2M
Cryoport, Inc. (CYRX) reported Q2 revenue of $49.0 million, surpassing FactSet's estimate of $48.2 million. The company, a provider of integrated, temperature-controlled supply chain solutions for life sciences, held its Q2 2026 Earnings Call on August 6, 2026. This financial update indicates a positive performance for the quarter, exceeding analyst expectations.
(CYRX) Price Dynamics and Execution-Aware Positioning
This article provides an in-depth analysis of Cryoport Inc. (NASDAQ: CYRX) price dynamics, highlighting a divergent sentiment across different time horizons and suggesting choppy market conditions. It outlines three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—each tailored to specific risk profiles and holding periods, and provides multi-timeframe signal analysis with support and resistance levels. The report also notes an exceptional 50.0:1 risk-reward short setup.
CryoPort, Inc. Revenue Breakdown – NASDAQ:CYRX
CryoPort, Inc. (NASDAQ: CYRX) generated $176.18 million USD in revenue last year, with its Life Sciences Services segment contributing the most at $101.03 million USD. The Americas region was the primary revenue source, accounting for $131.26 million USD. This indicates the company's strong performance in its core life sciences segment and a significant market presence in the Americas.
Enterprise value to EBITDA forward of CryoPort, Inc. – NASDAQ:CYRX
This article provides financial data for CryoPort, Inc. (NASDAQ:CYRX), specifically focusing on its Enterprise Value to EBITDA forward metric. The content appears to be a snapshot from a financial data platform, indicating key financial information without additional editorial analysis.
CYRX|Cryoport Inc|Price:15.330|Chg%:+0.400
This article provides a comprehensive stock analysis of Cryoport Inc (CYRX) by TradingKey, highlighting its healthy fundamentals, high growth potential, and fair valuation within the Freight & Logistics Services industry. The company's stock score is 7.18/10, with high institutional ownership and a "Buy" rating from multiple analysts, who forecast an upward trend in the medium term. Cryoport specializes in temperature-controlled supply chain solutions for Life Sciences, offering services and products like cryogenic biostorage and freezers.
CryoPort, Inc. Revenue Breakdown – DUS:CKX
CryoPort, Inc. (DUS:CKX) generated 150.00 million EUR in revenue last year, with its Life Sciences Services segment being the top performer, contributing 86.02 million EUR. The Americas region was the largest contributor to the company's revenue, accounting for 111.76 million EUR. This data provides a financial overview of CryoPort's revenue by segment and geography.
CryoPort Number of Employees 2026 | Employee Count & Headcount Data
CryoPort, Inc. (NASDAQ: CYRX) has 749 employees as of March 2026, representing a 9.3% increase since 2023. The company is actively hiring, with 50 job postings in 2026, though hiring velocity has slightly decreased. The workforce is primarily based in the United States, and the average salary is $84,257, with employee sentiment reported as negative and declining.
CryoPort, Inc. Revenue Breakdown – LSX:A14THD
CryoPort, Inc. (LSX:A14THD) generated 150.00 M EUR in revenue last year, primarily from its Life Sciences Services segment, which contributed 86.02 M EUR. The Americas region was the largest contributor, accounting for 111.76 M EUR. This article details the top segments and regional performance for the company.
Cryoport (CYRX) gets 13G/A update on Millennium-linked 3.4% stake
Cryoport (CYRX) received a Schedule 13G/A filing update revealing that Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander collectively reported beneficial ownership in the company's common stock. Integrated Core Strategies reported a 3.1% stake, while the Millennium entities and Mr. Englander each reported a 3.4% stake, noting that their cumulative beneficial ownership remains at 5% or less. The filing details shared voting and dispositive power for these entities.
Empire Financial Management Company LLC Acquires 98,714 Shares of CryoPort, Inc. $CYRX
Empire Financial Management Company LLC increased its stake in CryoPort, Inc. (NASDAQ:CYRX) by 24.4% in the first quarter, now owning 502,575 shares valued at $4,161,000. Other hedge funds also adjusted their positions, with institutional investors collectively owning 92.90% of the company's stock. CryoPort reported mixed financial results, and analysts hold a "Moderate Buy" rating with a consensus price target of $16.38, despite recent insider share sales.
Cryoport Inc (CYRX) Institutional Confidence
Cryoport Inc (CYRX) has an institutional shareholding score of 10.00, placing it first in its industry. The latest institutional shareholding proportion is 97.68%, a slight decrease from the previous quarter. First Eagle Investment is the largest institutional shareholder, holding 1.48% of outstanding shares.
Cryoport Inc (CYRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Cryoport Inc (CYRX), detailing its current price momentum, support and resistance levels, and insights from various technical indicators and moving averages. As of July 28, 2026, the stock is trading between resistance at $16.50 and support at $14.23, making it suitable for range-bound swing trading. While individual indicators show mixed signals (e.g., several 'Sell' signals for MACD, CCI, and Williams %R, but 'Buy' signals for MA100 and MA200), the overall technical rating based on moving averages suggests a Neutral signal.
CYRX|Cryoport Inc|Price:15.140|Chg%:-0.230
This article provides a detailed analysis of Cryoport Inc (CYRX) stock, including real-time quotes, key financial figures, and market trends. It highlights the company's strong fundamentals, high growth potential, and a "Buy" rating from analysts with a target price of $15.30. The content also delves into Cryoport's business model as a provider of temperature-controlled supply chain solutions for the life sciences industry.
Cryoport Inc (CYRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Cryoport Inc (CYRX) based on business segments and geographical regions. For the most recent fiscal year, Life Science products and BioLogistics solutions contributed almost equally to the majority of the company's revenue, with BioStorage/Bioservices making up a smaller portion. Regionally, the Americas account for the largest share of revenue, followed by Europe & Middle East & Africa (EMEA) and Asia Pacific.
Cryoport Inc (CYRX) Earnings Forecast: Future EPS & Revenue Growth Estimates
The article provides an earnings forecast for Cryoport Inc (CYRX), indicating a current earnings forecast score of 8.60 and a ranking of 7 out of 75 in the Freight & Logistics Services industry. Analysts have set an average price target of $13.00, with a consensus "Buy" rating based on 10 analysts. The expected revenue for the next quarter is $48.21M, and the EPS forecast for the next quarter is -$0.19.
Cryoport Inc (CYRX) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Cryoport Inc's (CYRX) dividend and stock split history. It notes that the company has distributed $0.00 in dividends over the past five years, indicating no recent dividend payouts. The article presents a table for dividend data, though it currently shows "No Data."
Granahan Investment Management LLC Purchases 190,938 Shares of CryoPort, Inc. $CYRX
Granahan Investment Management LLC significantly increased its stake in CryoPort, Inc. (NASDAQ:CYRX) by 475% in the first quarter, adding 190,938 shares to reach a total of 231,138 shares valued at $1.9 million. This move comes as CryoPort reported a narrower-than-expected loss in its latest earnings, alongside revenue that surpassed forecasts. Analysts largely maintain a "Buy" rating for CryoPort, with an average price target of $16.38, and some firms have recently raised their targets.
CYRX: Cell And Gene Recovery And Bioservices Differentiation Will Support Balanced Outlook
Cryoport's (CYRX) analyst price target has increased to $17.06, driven by improved conditions in cell and gene therapy markets and healthier growth in MVE, BioLogistics, and BioStorage segments. While bullish analysts highlight scaling services and regulatory tailwinds, more cautious views suggest considering execution risks in scaling operations. Recent news includes a revenue guidance increase for 2026 and a selection of its cryopreservation services by Verismo Therapeutics.
Cryoport Inc (CYRX) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Cryoport Inc (CYRX), listing major institutional holders and their proportion of shares. It also provides a breakdown of shareholder types, institutional shareholding trends over recent quarters, and a list of related ETFs that include CYRX. The data highlights key investors like Cadian Capital Management LP and Morgan Stanley & Co. LLC.
CryoPort, Inc. (NASDAQ:CYRX) Receives Average Recommendation of "Moderate Buy" from Brokerages
CryoPort, Inc. (NASDAQ:CYRX) has received an average "Moderate Buy" recommendation from nine brokerages, with an average 12-month price target of $16.38. Several analysts recently increased their price targets, indicating positive sentiment despite recent insider selling activities. The stock's current performance shows a 4.1% dip, trading at $15.37, while institutional investors maintain a significant 92.9% ownership.
CryoPort (NASDAQ:CYRX) Price Target Raised to $25.00 at BTIG Research
BTIG Research has increased its price target for CryoPort (NASDAQ:CYRX) to $25.00 from $17.00, maintaining a "buy" rating, which implies a potential upside of approximately 56%. Despite this positive outlook, the stock was down 2.4% to $16.03, and recent insider selling by the CFO and a director has been noted, although institutional investors hold a significant 92.9% stake in the company. CryoPort, a global provider of temperature-controlled logistics for the life sciences industry, reported mixed financial results for its last quarter, missing EPS estimates but exceeding revenue forecasts.
CYRX Maintained by BTIG -- Price Target Raised to $25.00
BTIG analyst David Larsen has maintained a 'Buy' rating for CryoPort (CYRX), raising the price target from $17.00 to $25.00, indicating increased confidence in the company's growth potential. Despite this bullish analyst sentiment, GuruFocus assesses CYRX as 45.1% overvalued with a GF Value™ of $11.05 against its current price of $16.03, and insider activity shows significant selling. Investors are advised to consider both the growth prospects and the current valuation risks.
Cryoport to Report Second Quarter 2026 Financial Results on August 6, 2026
Cryoport, Inc. (Nasdaq: CYRX) will announce its financial results for the second quarter ended June 30, 2026, on Thursday, August 6, 2026, after U.S. markets close. The company will also release a "Cryoport Second Quarter 2026 in Review" document and host a questions and answers conference call at 5:00 p.m. ET on the same day for investors. The call will be accessible via dial-in numbers and a live webcast, with replay options available afterward.
Cryoport to report Q2FY26 results on August 6
Cryoport, Inc. will announce its financial results for the second quarter ending June 30, 2026, on Thursday, August 6, 2026, after U.S. markets close. The company will also release a detailed "Cryoport Second Quarter 2026 in Review" document at 4:05 p.m. ET, followed by a conference call at 5:00 p.m. ET to discuss the results and answer investor questions. Replays of the call will be available online and via dial-in until August 13, 2026.
Cryoport to Report Second Quarter 2026 Financial Results on August 6, 2026
Cryoport, Inc. announced it will release its second-quarter financial results for 2026 on Thursday, August 6, 2026, after U.S. markets close. The company will also issue a detailed "Cryoport Second Quarter 2026 in Review" document and host a Q&A conference call at 5:00 p.m. ET on the same day. This call will provide an opportunity for the investment community to discuss the company's financial and operational performance.
Cryoport schedules Q2 results and a 5 p.m. Q&A for Aug. 6
Cryoport (Nasdaq: CYRX) announced it will report its second-quarter 2026 financial results on Thursday, August 6, 2026, after U.S. markets close. The company will also release a detailed "Cryoport Second Quarter 2026 in Review" document at 4:05 p.m. ET, followed by a Q&A conference call hosted by management at 5:00 p.m. ET. Investors can access the call via dial-in numbers or a live webcast on the company's investor relations website, with replays available afterward.
CryoPort Inc (CYRX) Stock Down 4.8% but Still Overvalued -- GF Score: 68/100
CryoPort Inc (CYRX) shares fell 4.8% to $15.71 on July 20, 2026, and are deemed "Significantly Overvalued" by GuruFocus, trading 42.3% above its GF Value™ estimate of $11.04. The company's GF Score™ is 68/100, indicating strengths in growth and momentum but weaknesses in profitability and valuation. Insider selling of $3.6 million with no buying activity in the last three months further suggests caution for investors.
CryoPort Inc (CYRX) Stock Down 4.8% but Still Overvalued -- GF S
CryoPort Inc (CYRX) shares recently fell by 4.8% to $15.71 but are still considered significantly overvalued by GuruFocus' GF Value™ estimate of $11.04. The stock's GF Score™ is 68/100, indicating strengths in growth and momentum but weaknesses in profitability and valuation. Insider selling activity, totaling $3.6 million over the last three months with no buying, further suggests caution for investors.
Cryoport stock trades steady as revenue grows and losses narrow
Cryoport stock is showing steady trading as the company increases revenue while working to reduce losses and manage debt following recent acquisitions. The firm specializes in temperature-controlled logistics and biostorage for the life sciences industry, particularly for advanced therapies. Investors are closely monitoring how increased demand for logistics and storage services will translate into improved profitability and cash flow, as the company balances growth investments with financial discipline.
Analysts Offer Insights on Industrial Goods Companies: CryoPort (CYRX), Latham Group (SWIM) and Intuitive Machines (LUNR)
Three industrial goods companies, CryoPort (CYRX), Latham Group (SWIM), and Intuitive Machines (LUNR), have received bullish sentiments from analysts. CryoPort received a Buy rating from Craig-Hallum with an average price target indicating a potential downside, while Latham Group also got a Buy rating from Craig-Hallum with a Hold consensus. Intuitive Machines was granted a Buy rating from Craig-Hallum, holding a Moderate Buy consensus with a higher price target.
